A sponsored article from Diaceutics, published by BioPharma Dive, contends that targeted therapies are failing to reach many eligible patients because of breakdowns in diagnostic and care pathways rather than shortcomings in science. The company cites its own research in advanced non-small cell lung cancer, estimating that roughly 64% of eligible patients do not receive the appropriate targeted therapy, and that about 29% are lost even after a diagnostic test identifies an actionable biomarker.
The proposed fix is a commercialization model built around real-time identification of practice gaps, support for laboratory infrastructure, and contextual education for clinicians at the point of prescribing. Diaceutics says this approach has produced a 35% uplift in new therapy starts, an 8% increase in market share for a top-10 pharma client within 12 months, and a 19% increase in actionable care targets. It also describes a rare-disease program that identified 121 eligible patients, generating $2M in revenue and a 70% ROI.
Because the piece is sponsored content from Diaceutics, the claims are the company's own and are not independently verified. The article frames the challenge as an industry-wide need to move from retrospective analysis to prospective action, using diagnostic intelligence to connect more patients to the right therapy. No other sources were provided for comparison.